Video

Inotuzumab as an Option for Patients with R/R Acute Lymphoblastic Leukemia

Author(s):

Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Elias Jabbour, MD, MD Anderson Cancer Center

Dr Jabbour and fellow panelists share their thoughts on the benefits of Inotuzumab ozogamicin, particularly in a pre-allogeneic HSCT setting.

Related Videos
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment